Subtopic Deep Dive
Temozolomide in Glioma Treatment
Research Guide
What is Temozolomide in Glioma Treatment?
Temozolomide (TMZ) is an oral alkylating agent used as standard chemotherapy combined with radiotherapy for newly diagnosed glioblastoma, improving survival as shown in the Stupp protocol.
The Stupp et al. (2005) trial established concomitant and adjuvant TMZ with radiotherapy, yielding a median survival of 14.6 months versus 12.1 months with radiotherapy alone (20,954 citations). MGMT promoter methylation predicts TMZ response by impairing DNA repair. Subsequent trials explore combinations like Tumor-Treating Fields (Stupp et al., 2017, 2,429 citations).
Why It Matters
TMZ defines standard-of-care for glioblastoma, the most lethal glioma, extending survival from months to over a year (Stupp et al., 2005). MGMT methylation testing guides patient selection, optimizing therapy and reducing futile treatments (Hegi et al., referenced in Weller et al., 2020). Combination strategies with bevacizumab or TTFields aim to overcome resistance, impacting clinical guidelines (Gilbert et al., 2014; Stupp et al., 2017). Epidemiological data highlight persistent high mortality, underscoring need for TMZ refinements (Ostrom et al., 2014).
Key Research Challenges
TMZ Resistance Mechanisms
Glioblastoma cells develop resistance via MGMT repair, cancer stem cells, and DNA damage tolerance (Liu et al., 2006). CD133+ stem cells show chemoresistance linked to gene expression profiles (1,769 citations). Overcoming this limits long-term survival gains.
MGMT Biomarker Variability
MGMT promoter methylation status varies across tumors, affecting TMZ efficacy prediction (implied in Stupp et al., 2005). Assay standardization remains inconsistent despite guideline recommendations (Weller et al., 2020). False negatives reduce treatment precision.
Optimizing Combination Regimens
Adding bevacizumab prolongs progression-free but not overall survival (Gilbert et al., 2014, 2,706 citations). TTFields with TMZ improves outcomes but requires validation (Stupp et al., 2017). Toxicity and cost hinder widespread adoption.
Essential Papers
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · 2005 · New England Journal of Medicine · 21.0K citations
The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Roger E. McLendon · 2008 · Nature · 7.6K citations
Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilo...
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert, James J. Dignam, Terri S. Armstrong et al. · 2014 · New England Journal of Medicine · 2.7K citations
First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement ...
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · 2017 · JAMA · 2.4K citations
clinicaltrials.gov Identifier: NCT00916409.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari, Tim R. Fenton, Robert Bachoo et al. · 2007 · Genes & Development · 2.3K citations
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion t...
The epidemiology of glioma in adults: a "state of the science" review
Quinn T. Ostrom, Luc Bauchet, Faith G. Davis et al. · 2014 · Neuro-Oncology · 2.2K citations
Gliomas are the most common primary intracranial tumor, representing 81% of malignant brain tumors. Although relatively rare, they cause significant mortality and morbidity. Glioblastoma, the most ...
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
Quinn T. Ostrom, Haley Gittleman, Gabrielle Truitt et al. · 2018 · Neuro-Oncology · 2.2K citations
Breast (female only)Prostate (male only)
Reading Guide
Foundational Papers
Start with Stupp et al. (2005) for TMZ standard (20,954 citations), then McLendon (2008) for genomic context enabling MGMT discovery, followed by Gilbert et al. (2014) for combo trial design.
Recent Advances
Study Stupp et al. (2017) for TTFields + TMZ survival data and Weller et al. (2020) EANO guidelines integrating biomarkers and regimens.
Core Methods
Concomitant/adjuvant TMZ dosing (Stupp et al., 2005); MGMT methylation assays; Kaplan-Meier survival analysis in RCTs; genomic profiling via TCGA (McLendon, 2008).
How PapersFlow Helps You Research Temozolomide in Glioma Treatment
Discover & Search
Research Agent uses searchPapers and citationGraph on 'Temozolomide glioblastoma MGMT' to map Stupp et al. (2005, 20,954 citations) as central node, revealing resistance papers like Liu et al. (2006). exaSearch uncovers trial protocols; findSimilarPapers links to Stupp et al. (2017).
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Stupp et al. (2005), then runPythonAnalysis with pandas to compute hazard ratios and GRADE evidence as high-quality RCT. verifyResponse (CoVe) cross-checks MGMT data against Weller et al. (2020) guidelines for statistical verification.
Synthesize & Write
Synthesis Agent detects gaps in TMZ resistance literature via contradiction flagging between stem cell data (Liu et al., 2006) and genomic pathways (McLendon, 2008). Writing Agent uses latexEditText, latexSyncCitations for Stupp trial figures, and latexCompile to generate review manuscripts with exportMermaid for resistance pathway diagrams.
Use Cases
"Extract survival data from Stupp 2005 TMZ trial and plot Kaplan-Meier curves"
Research Agent → searchPapers('Stupp temozolomide 2005') → Analysis Agent → readPaperContent → runPythonAnalysis (pandas/matplotlib for KM plots, GRADE high) → researcher gets CSV-exported curves with p-values.
"Draft LaTeX review on TMZ + TTFields with citations"
Synthesis Agent → gap detection (TMZ combos) → Writing Agent → latexEditText('TMZ TTFields section') → latexSyncCitations([Stupp2005,Stupp2017]) → latexCompile → researcher gets PDF manuscript with synced refs.
"Find code for MGMT methylation analysis from glioma papers"
Research Agent → citationGraph('MGMT temozolomide') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for methylation classifiers linked to TCGA data (McLendon 2008).
Automated Workflows
Deep Research workflow scans 50+ TMZ papers via searchPapers → citationGraph → structured report on efficacy by MGMT status (Stupp et al., 2005). DeepScan applies 7-step CoVe to verify resistance claims from Liu et al. (2006) with runPythonAnalysis checkpoints. Theorizer generates hypotheses on TMZ combos from Stupp (2017) and Gilbert (2014) trial contradictions.
Frequently Asked Questions
What defines Temozolomide use in glioma?
TMZ is given concomitantly with radiotherapy (75 mg/m² daily) then adjuvantly (150-200 mg/m² for 5 days every 28 days) for glioblastoma per Stupp et al. (2005).
What methods predict TMZ response?
MGMT promoter methylation by methylation-specific PCR or pyrosequencing predicts benefit, as referenced in EANO guidelines (Weller et al., 2020).
What are key papers?
Stupp et al. (2005, NEJM, 20,954 citations) established standard; Stupp et al. (2017, JAMA, 2,429 citations) added TTFields; Gilbert et al. (2014, NEJM, 2,706 citations) tested bevacizumab.
What open problems exist?
Overcoming resistance in unmethylated MGMT tumors and standardizing combinations like TTFields without added toxicity (Stupp et al., 2017; Weller et al., 2020).
Research Glioma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Temozolomide in Glioma Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Glioma Diagnosis and Treatment Research Guide